							Sheet	1 of 1		
APPLICANT FACSIMILE OF FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE					ATTY DOCKET NO SERIAL NO.					
REV 7-80 PATENT AND TRADÉMARK OFFICE					MBI-008 09/512, <del>581</del>			Ē,		
LIST OF PUBLICATIONS CITED BY APPLICANT					APPLICANT					
(Use several sheets if necessary)					Ana M. Soto et al.					
					February 24, 2000 MAR 0 9 2001				칠	
			·		Trebladiy 24, 2000	<u></u>	12	<u>, 6</u>	<del>}                                    </del>	
			U.S	S. PATENT DOCL	JMENTS		WY & TO	DEMARK		
EXAMINER		DOCUMENT NUMBER	DATE	DATE NAME CLASS			SUBCLASS FILING DATE			
INITIAL							IF APPROPRIATE			
					(					
			FORE	IGN PATENT DO	CUMENTS	·				
		DOCUMENT NUMBER	DATE	d	COUNTRY	OLASS	SUBCLASS TRANSLATIO		LATION	
								. <del>¥Es</del>	- NO-	
SR	C1	WO 9731531	9/97	PCT						
<del> </del>				•						
					te, Pertinent Pages;					
SR	C2				OTEIN SEQUENCES	TEIN SEQUENCES September 11, 1996,				
7.6 Cocco. Human Breeze region,						0-7045	70			
		DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES January 30, 1997, AC=Z8457, Human DNA sequence from PAC 49J10, BRCA2 gene region chromosome 13q12-13 contains								
Human DNA sequence from PAC 49J10, BRCA2 gene region chromos ESTs;						10111030111	me roqra-ro contains			
C4 DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES November 1, 1999, AC=0							AC=Q9Y	215		
SR		KIAA0979 PROTIEN (FRAGMENT);								
5R	C5	DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES January 25, 2000, AC=AL137201								
	L	Novel human gene mapping to chromosome 13.								
5R	C6			EOTIDE AND PROTEIN SEQUENCES March 31, 1999, AC=U9582					5,	
7.		Human androgen-induced prostate proliferative shutoff associated protein (AS3) mRNA;								
					<b>a</b>					
	$\vdash$						•	-		
1	I					•				

Examiner

Date Considered

14/01

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



APPLICANT FACSIMILE OF FORM PTO-1449 U.S. DEPARTMENT OF ATTY DOCKET NO SERIAL NO.											
COMMERCE REV 7-80 PATENT AND TRADEMARK OFF			MERCE	MBI-008 09/512,581							
UST OF PUBLICATIONS CITED BY APPLICANT					APPLICANT						
(Vegeveral sheets if necessary)				Ana M. Soto et al.							
/0	. 16	on Egy			FILING DATE GROUP						
4	47.	(6)			February 24, 2000						
/ W.	•	<i>\$</i>	U.S	S. PATENT DOCU	JMENTS						
EXAMINE	EXAMINATANT & TRANSPORTED TO NUMBER		DATE	NAME		CLASS	SUBCLASS	FILING DATE			
INITIAL								IF APPROPRIATE			
									_		
			FORE	IGN PATENT DO	CUMENTS						
	DOCUMENT NUMBER			c	COUNTRY CLASS SUBCLASS				SLATION		
	<del>                                     </del>						<u> </u>	YES	NO		
		<u> </u>		<u> </u>		,	1				
	Y 1				te, Pertinent Pages,						
İ	A1	Denison SH, et al. Mutation in the bimD gene of Aspergillus nidulans confers a									
5R			mitotic block and sensitivity to DNA damaging agents. Genetics. 1993								
	A2		Aug;134(4):1085-96;  Geck P, et al. Expression of novel genes linked to the androgen-induced, proliferative								
	~	· · · · · · · · · · · · · · · · · · ·	_	71							
shutoff in prostate cancer cells. J Steroid			на Бюспет Мої Бюї. 1997 Nov-Dec;03(4-0):211-								
	A3	8;									
gr	/~		Geck P, et al. Early gene expression during androgen-induced inhibition of proliferation of prostate cancer cells: a new suppressor candidate on chromosome 13, in the BRCA2-								
13.0		_									
	A4	Rb1 locus. <i>J Steroid Biochem Mol Biol</i> . 1999 Jan;68(1-2):41-50;  Koch C, et al. A role for the transcription factors Mbp1 and Swi4 in progression from G1									
SR	to S phase. Science. 1993 Sep 17;261(5128):1551-7;							JIII O I			
Sadar MD, et al. Prostate cancer: molecular biology of early progression to androgen							en				
SR		independence. Endocr Relat Cancer. 1999 Dec;6(4):487-502;									
Soto AM, et al. Variants of the human prostate LNCaP cell line as tools to study discr								screte			
5n	Solo Alvi, et al. Variants of the human prostate Linear cell line as tools to							-			
		11):545-58;							•		
					on the proliferation of human breast tumor cells						
SR		(MCF-7). J Steroid Biochem. 1985 Jul;23(1):87-94;									
Ca	A8								static		
SR											
Pote Considered											
1/14/											
EXAMIN	EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										

	FACSIMIL	E OF	FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO	SERIAL NO.				
REV 7-80			PATENT AND TRADEMARK OFFICE	MBI-008	09/512,581				
LIS			JBLICATIONS CITED BY APPLICANT e several sheets if necessary)	Ana M. Soto et al.					
0		(US	e several streets if frecessary)	FILING DATE	GROUP				
(\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		Ż		February 24, 2000					
1	MOD	, CO	OTHERS (including Author, Title, Dat	te, Pertinent Pages, Etc.)					
STEM & T	B1 ADEM	ME	Tulinius H, et al. Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. <i>BMJ</i> . 1992 Oct 10;305(6858):855-7;						
SR	<b>B</b> 2		Waddick KG, et al. Innovative treatment programs against cancer: II. Nuclear factor-kappaB (NF-kappaB) as a molecular target. <i>Biochem Pharmacol</i> . 1999 Jan 1;57(1):9-17;						
sr	В3		Zhang Y, et al. Molecular characteriza promoter. <i>Biochim Biophys Acta</i> . 199	· ·	ent kinase inhibitor p27				
					-				
Examine	er	_/	Randon	Date Considered					
EXAMIN	NER:	<del>-1</del>	Initial if reference considered, whether or not if not in conformance and not considered. In	citation is in conformance with MPE					